KING PHARMACEUTICALS SIGNS INTELLECTUAL PROPERTY DEAL

King Pharmaceuticals officials signed a $35 million agreement Friday to acquire intellectual property from a privately held generic drug-maker based in Philadelphia. That company, Mutual Pharmaceutical Co., has developed new methods for administering and dosing metaxalone, the active ingredient in King's popular Skelaxin muscle relaxant. King gained worldwide rights to use those new methods under the terms of the agreement.

Bristol Herald Courier (http://www.tricities.com/servlet/Satellite?pagename=TRI%2FMGArticle%2FTRI_BasicArticle&c=MGArticle&cid=1128768638958)